Abcam completes $340m strategic acquisition and expands kit capacity and capability
– Completing $340m strategic acquisition of BioVision – Expanding facilities in Eugene, further growing kits and assays portfolio – Supporting the growing demand of the sector and accelerating execution of strategic plan Abcam (AIM:ABC; NASDAQ:ABCM), a global innovator in life sciences reagents and tools, today announces the successful completion of its acquisition of BioVision and the expansion of its immunoassay […]
